Loading...

Home
ETF
CANF

CANF

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

CANF News

Can-Fite BioPharma Completes Enrollment of 247 Patients in Phase 3 Study

2d agoYahoo Finance

Can-Fite BioPharma Completes Patient Enrollment for Psoriasis Clinical Trial

2d agoNewsfilter

Stock Futures Dip Ahead of Independence Day as Investors Remain Cautious

6d agoseekingalpha

Biotech Companies See Significant Stock Gains

6d agoNASDAQ.COM

Can-Fite BioPharma Reports Positive Results in Pancreatic Cancer Study

Jul 01 2026stocktwits

Can-Fite BioPharma's Phase 2a Study Shows Promising Results

Jul 01 2026NASDAQ.COM

Can-Fite BioPharma Achieves Breakthrough in Pancreatic Cancer Study

Jul 01 2026Yahoo Finance

Can-Fite Secures Japanese Patent for Obesity Treatment

Jun 26 2026stocktwits

Can-Fite Secures Japanese Patent Enhancing Market Position

Jun 26 2026Newsfilter

Can-Fite BioPharma to Attend BIO International Convention

Jun 17 2026Newsfilter

Can-Fite BioPharma Publishes Canine Osteoarthritis Study Results

May 18 2026Newsfilter

Can-Fite BioPharma Reports Positive Clinical Data for Namodenoson

Apr 30 2026Newsfilter

Can-Fite Signs Up to $325M Deal with Vetbiolix

Mar 30 2026Newsfilter

Can-Fite Biopharma Reports FY 2025 Financial Results

Mar 26 2026seekingalpha

Can-Fite BioPharma Reports 2025 Financial Results and Clinical Advances

Mar 26 2026Newsfilter

CAN-FITE ANNOUNCES 2025 FINANCIAL RESULTS AND CLINICAL ADVANCEMENTS, SHOWCASING PROMISING PHASE 2A DATA FOR PANCREATIC CANCER AND NINE-YEAR CANCER-FREE SURVIVAL IN LIVER CANCER PATIENTS

Mar 26 2026moomoo